Management Team
Dr. Peter Kash is a co-founder and Vice-Chairman of TargImmune Therapeutics (Switzerland). He was formerly a co-founder and partner and Chairman of Two River Group and President of Riverbank Capital Securities specializing in creating and financing several biotech companies including Kite Pharma, Edgemont Pharmaceuticals, and Intercept Pharmaceuticals. He has cofounded more than a dozen biotech companies and raised in excessive of $2 billion in private/public financing, creating more than $20 billion in peak aggregate market value. Dr. Kash has worked on Wall Street for 30 years including at Shearson Lehman Hutton and Paramount Capital. At Paramount he co-founded and financed PolaRx Biopharmaceuticals; developing the first cancer drug from China, Trisenox approved by the FDA. The portfolio companies have received a total of 6 FDA approvals to date.
From 1990-1992 he was an Associate Professor of Marketing at Polytechnic University. During 1996-2000 he was an Adjunct Professor of Entrepreneurship at the Wharton Business School. During 2000-2002 he was a Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo and in 2015 a Visiting Professor at Hebrew University. He has frequently lectured and served as a Keynote Speaker worldwide in many of the 70 countries he has visited.
His education includes a B.S. in Management Science from S.U.N.Y. Binghamton and an MBA in International Banking and Finance from the Lubin School of Business at Pace University. He holds a Doctorate in Education at The Azrieli Graduate School of Yeshiva University. Dr. Kash completed post graduate classes on Making Boards of Directors More Effective at Harvard Business School.
He has authored several books including the international best seller Make Your Own Luck, (Prentice Hall), now in 8 languages distributed in more than 70 countries and (international bestseller Freedom From Disease (St. Martin’s Press). His third book Take Two Tablets Medicine from the Bible. You might have seen Peter as a television host for FNN’s and as a guest on CNBC, Fox and Friends, Show, WB11, or with Dr. Oz Radio Show, and more recently at his first Tedx lecture in London 2019.
Dr. Peter Kash is a co-founder and Vice-Chairman of TargImmune Therapeutics (Switzerland). He was formerly a co-founder and partner and Chairman of Two River Group and President of Riverbank Capital Securities specializing in creating and financing several biotech companies including Kite Pharma, Edgemont Pharmaceuticals, and Intercept Pharmaceuticals. He has cofounded more than a dozen biotech companies and raised in excessive of $2 billion in private/public financing, creating more than $20 billion in peak aggregate market value. Dr. Kash has worked on Wall Street for 30 years including at Shearson Lehman Hutton and Paramount Capital. At Paramount he co-founded and financed PolaRx Biopharmaceuticals; developing the first cancer drug from China, Trisenox approved by the FDA. The portfolio companies have received a total of 6 FDA approvals to date.
From 1990-1992 he was an Associate Professor of Marketing at Polytechnic University. During 1996-2000 he was an Adjunct Professor of Entrepreneurship at the Wharton Business School. During 2000-2002 he was a Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo and in 2015 a Visiting Professor at Hebrew University. He has frequently lectured and served as a Keynote Speaker worldwide in many of the 70 countries he has visited.
His education includes a B.S. in Management Science from S.U.N.Y. Binghamton and an MBA in International Banking and Finance from the Lubin School of Business at Pace University. He holds a Doctorate in Education at The Azrieli Graduate School of Yeshiva University. Dr. Kash completed post graduate classes on Making Boards of Directors More Effective at Harvard Business School.
He has authored several books including the international best seller Make Your Own Luck, (Prentice Hall), now in 8 languages distributed in more than 70 countries and (international bestseller Freedom From Disease (St. Martin’s Press). His third book Take Two Tablets Medicine from the Bible. You might have seen Peter as a television host for FNN’s and as a guest on CNBC, Fox and Friends, Show, WB11, or with Dr. Oz Radio Show, and more recently at his first Tedx lecture in London 2019.
Dr. Kash graduated Cum Laude from the University of Florida’s College of Health and Human Performance with a Bachelor’s in Applied Physiology and Kinesiology. He later went on to receive his Doctor of Chiropractic and Master of Science degree in Applied Clinical Nutrition from Northeast College of Health Sciences. He practiced Functional Medicine in the pursuit of treating the root cause of disease and lectures on topics related to the field. Dr. Kash is a co-founder of Belum Therapeutics, Advanced Concepts in Biology, and Opris Biotechnologies. Author of The Autoimmune Plague: Regain Sovereignty Over Your Body and Life
Dr. Kash graduated Cum Laude from the University of Florida’s College of Health and Human Performance with a Bachelor’s in Applied Physiology and Kinesiology. He later went on to receive his Doctor of Chiropractic and Master of Science degree in Applied Clinical Nutrition from Northeast College of Health Sciences. He practiced Functional Medicine in the pursuit of treating the root cause of disease and lectures on topics related to the field. Dr. Kash is a co-founder of Belum Therapeutics, Advanced Concepts in Biology, and Opris Biotechnologies. Author of The Autoimmune Plague: Regain Sovereignty Over Your Body and Life
Mr. Matthew Bronfman is the Chairman and CEO of BHB Holdings, a private investment firm with numerous interests. He served as Chairman of Bronfman Rothschild, a Washington, D.C. based Registered Investment Advisor. In addition, Mr. Bronfman controls the IKEA franchise in Israel and has numerous real estate holdings there and in the U.S. He also serves as Chairman of Lincoln Avenue Capital an affordable housing investment firm, and Bronfman LLC, a provider of growth capital for private companies. Prior to starting BHB, Mr. Bronfman was a partner at ACI Capital, private equity firm in NYC. ACI portfolio companies included Accent Energy, Sundance Catalogue, and Jenny Craig. Prior to that, Mr. Bronfman was the Chairman and Chief Executive Officer of Sterling Cellular Holdings, LP, a privately held cellular telephone company. Previously, he was employed by Goldman Sachs & Co. and Cadillac Fairview Corporation Limited. He received a BA from Williams College in 1981 and an MBA from Harvard Business School in 1985.
Mr. Matthew Bronfman is the Chairman and CEO of BHB Holdings, a private investment firm with numerous interests. He served as Chairman of Bronfman Rothschild, a Washington, D.C. based Registered Investment Advisor. In addition, Mr. Bronfman controls the IKEA franchise in Israel and has numerous real estate holdings there and in the U.S. He also serves as Chairman of Lincoln Avenue Capital an affordable housing investment firm, and Bronfman LLC, a provider of growth capital for private companies. Prior to starting BHB, Mr. Bronfman was a partner at ACI Capital, private equity firm in NYC. ACI portfolio companies included Accent Energy, Sundance Catalogue, and Jenny Craig. Prior to that, Mr. Bronfman was the Chairman and Chief Executive Officer of Sterling Cellular Holdings, LP, a privately held cellular telephone company. Previously, he was employed by Goldman Sachs & Co. and Cadillac Fairview Corporation Limited. He received a BA from Williams College in 1981 and an MBA from Harvard Business School in 1985.
Dr. Josh Sharan graduated with multiple honors recognitions from Nova Southeastern University’s College of Osteopathic Medicine. He has performed extensive research in the field of regenerative medicine, describing in literature multiple first in human responses to mesenchymal stem cell therapy for various orthopedic and autoimmune conditions. Much of his work has been presented at the International Cartilage Regeneration Society conference and published in peer reviewed journals. Dr. Sharan is a cofounder of Opris Biotechnologies and Florida Biotechnologies, both of which are focused on therapeutics for rare pediatric diseases. Dr. Sharan leads the preclinical and clinical development of Camelot BioCapital’s pipeline.
Dr. Josh Sharan graduated with multiple honors recognitions from Nova Southeastern University’s College of Osteopathic Medicine. He has performed extensive research in the field of regenerative medicine, describing in literature multiple first in human responses to mesenchymal stem cell therapy for various orthopedic and autoimmune conditions. Much of his work has been presented at the International Cartilage Regeneration Society conference and published in peer reviewed journals. Dr. Sharan is a cofounder of Opris Biotechnologies and Florida Biotechnologies, both of which are focused on therapeutics for rare pediatric diseases. Dr. Sharan leads the preclinical and clinical development of Camelot BioCapital’s pipeline.
Dr. Friedland is a physician with over 25 years of experience in clinical medicine and an international advisor to many Fortune and Forbes global companies. She consults with healthcare, biotech, corporate, and financial institutions. Among her roles, Dr. Friedland is the head of Business Development at Firebrick Pharma (Australia), senior consultant to TargImmune Therapeutics (Basel, Switzerland), co-founder, and director of FFD Capital LLC (USA), and Medical Officer for the Anti- Inflammaging Company (Dubai, UAE). Dr. Friedland is also a non-executive director on several Healthcare boards. An author of seven healthcare-related bestsellers with a long career in television
and health media, she has developed public health and disease management programs in Asia, USA, Australia, Africa, and the UK and delivered keynote addresses in more than 30 countries.
Dr. Friedland is a physician with over 25 years of experience in clinical medicine and an international advisor to many Fortune and Forbes global companies. She consults with healthcare, biotech, corporate, and financial institutions. Among her roles, Dr. Friedland is the head of Business Development at Firebrick Pharma (Australia), senior consultant to TargImmune Therapeutics (Basel, Switzerland), co-founder, and director of FFD Capital LLC (USA), and Medical Officer for the Anti- Inflammaging Company (Dubai, UAE). Dr. Friedland is also a non-executive director on several Healthcare boards. An author of seven healthcare-related bestsellers with a long career in television
and health media, she has developed public health and disease management programs in Asia, USA, Australia, Africa, and the UK and delivered keynote addresses in more than 30 countries.
Dr. Rice graduated with honors from Nova Southeastern University’s College of Osteopathic Medicine. As Vice President, with a background in both business and healthcare, Dr. Rice is responsible for identifying and pursuing new business opportunities. He assists all C-suite personnel and spends much of his focus in the preclinical and clinical development of the company’s therapeutics. Through a combination of strategic planning, market analysis, and scientific acumen, Dr. Rice advances Camelot’s therapeutic programs.
Dr. Rice graduated with honors from Nova Southeastern University’s College of Osteopathic Medicine. As Vice President, with a background in both business and healthcare, Dr. Rice is responsible for identifying and pursuing new business opportunities. He assists all C-suite personnel and spends much of his focus in the preclinical and clinical development of the company’s therapeutics. Through a combination of strategic planning, market analysis, and scientific acumen, Dr. Rice advances Camelot’s therapeutic programs.
Scientific & IP Advisory Board
Dr. Durrant is an entrepreneur, board member, C-level executive, former big pharma executive, and an MD by original training. He is Chairman and CEO of Humanigen, a Nasdaq-listed public company developing biologics for a range of serious and life-threatening conditions. His specialty is both startups and turnarounds, including brands and business units as well as companies. He has served as board chairman, and lead independent director for both private and public companies. He has four successful exits. Additionally, he served as head of infectious disease at Johnson & Johnson and other blue-chip companies. In addition, he has raised several hundred million dollars from a variety of sources and has been an executive at several blue-chip big pharma companies, and held business unit P+L and staff roles, both in the US and globally. He is a founding director of a private nanotech and a board member of a private gene therapy company.
Dr. Durrant is an entrepreneur, board member, C-level executive, former big pharma executive, and an MD by original training. He is Chairman and CEO of Humanigen, a Nasdaq-listed public company developing biologics for a range of serious and life-threatening conditions. His specialty is both startups and turnarounds, including brands and business units as well as companies. He has served as board chairman, and lead independent director for both private and public companies. He has four successful exits. Additionally, he served as head of infectious disease at Johnson & Johnson and other blue-chip companies. In addition, he has raised several hundred million dollars from a variety of sources and has been an executive at several blue-chip big pharma companies, and held business unit P+L and staff roles, both in the US and globally. He is a founding director of a private nanotech and a board member of a private gene therapy company.
Dr. Pombo-Villar is currently the CTO of TargImmune Therapeutics AG in Switzerland. He held the post of CEO position from its seed stage in 2017 until August 2021. Under his leadership, the company developed the innovative targeted immunooncology platform and its lead project into IND-enabling studies, established the operations in Basel, and raised over CHF 47 million. He studied Chemistry at the University of Warwick where he obtained his Ph.D., MSc, and BSc. He completed his post-doctoral studies at the ETH Zürich in prebiotic chemistry and organic chemistry under Prof. A Eschenmoser. He spent 23 years in drug discovery and development at Sandoz and Novartis, as well as held several roles in business development functions, and was head of alliance management at the Novartis Institute for Biomedical Research (NIBR), where he focused on creating and managing the company’s collaborative efforts. Prior to joining TargImmune, he was chief operations officer and a Board Member of Oxford BioTherapeutics (OBT) overseeing the UK -based biotech’s newly created development operations in Basel. Dr. Pombo-Villar is a Fellow of the Royal Society of Chemistry, a member of several scientific societies, and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US).
Dr. Pombo-Villar is currently the CTO of TargImmune Therapeutics AG in Switzerland. He held the post of CEO position from its seed stage in 2017 until August 2021. Under his leadership, the company developed the innovative targeted immunooncology platform and its lead project into IND-enabling studies, established the operations in Basel, and raised over CHF 47 million. He studied Chemistry at the University of Warwick where he obtained his Ph.D., MSc, and BSc. He completed his post-doctoral studies at the ETH Zürich in prebiotic chemistry and organic chemistry under Prof. A Eschenmoser. He spent 23 years in drug discovery and development at Sandoz and Novartis, as well as held several roles in business development functions, and was head of alliance management at the Novartis Institute for Biomedical Research (NIBR), where he focused on creating and managing the company’s collaborative efforts. Prior to joining TargImmune, he was chief operations officer and a Board Member of Oxford BioTherapeutics (OBT) overseeing the UK -based biotech’s newly created development operations in Basel. Dr. Pombo-Villar is a Fellow of the Royal Society of Chemistry, a member of several scientific societies, and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US).
Dr. Mitchell is Co-Founder, President, and Chairman of iOncologi, Inc., a biotechnology ‘spinout’ company from the University of Florida (UF) specializing in immuno-oncology. Dr. Mitchell is the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery at UF. He serves as Director of the UF Clinical Translational Science Institute (CTSI) and Co-Director of the Preston A. Wells, Jr. Center for Brain Tumor Therapy. Under Dr. Mitchell’s leadership, the Wells Brain Tumor Center has grown to one of the largest brain tumor centers in the United States, with over 100 fulltime employees dedicated to brain tumor research and clinical care and drawing patients from over 39 states and internationally for novel brain tumor treatments. He graduated from the Medical Scientist Training Program (MD/Ph.D.) at Duke University Medical Center and completed postgraduate training in pathology and neurooncology research prior to joining the faculty at Duke in 2005 as an Assistant Professor. He has advanced discoveries from his laboratory through the successful issuance of six FDA-approved investigational new drugs (IND) applications and has led the clinical evaluation of several novel brain tumor immunotherapies through ten first-in-human clinical trials and multi-center phase 2 studies. His research has been supported by the NIH, Department of Defense, and numerous private funding agencies Dr. Mitchell is an inventor of over 25 filed patents for novel cancer immunotherapies, several of which have been licensed by pharmaceutical companies for commercial development.
Dr. Mitchell is Co-Founder, President, and Chairman of iOncologi, Inc., a biotechnology ‘spinout’ company from the University of Florida (UF) specializing in immuno-oncology. Dr. Mitchell is the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery at UF. He serves as Director of the UF Clinical Translational Science Institute (CTSI) and Co-Director of the Preston A. Wells, Jr. Center for Brain Tumor Therapy. Under Dr. Mitchell’s leadership, the Wells Brain Tumor Center has grown to one of the largest brain tumor centers in the United States, with over 100 fulltime employees dedicated to brain tumor research and clinical care and drawing patients from over 39 states and internationally for novel brain tumor treatments. He graduated from the Medical Scientist Training Program (MD/Ph.D.) at Duke University Medical Center and completed postgraduate training in pathology and neurooncology research prior to joining the faculty at Duke in 2005 as an Assistant Professor. He has advanced discoveries from his laboratory through the successful issuance of six FDA-approved investigational new drugs (IND) applications and has led the clinical evaluation of several novel brain tumor immunotherapies through ten first-in-human clinical trials and multi-center phase 2 studies. His research has been supported by the NIH, Department of Defense, and numerous private funding agencies Dr. Mitchell is an inventor of over 25 filed patents for novel cancer immunotherapies, several of which have been licensed by pharmaceutical companies for commercial development.
Fumihiko “Fumi” Urano, MD, PhD, FACMG, is a Physician and Medical Researcher specializing in Wolfram syndrome, characterized by juvenile-onset diabetes, vision loss, and brain system disruption. Dr. Urano is a Professor of Medicine and Pathology & Immunology, an attending physician, and currently holds Samuel E. Schechter Endowed Professorship in Medicine at Washington University School of Medicine. Dr. Urano is a driving force in the study of Wolfram syndrome and Wolfram-spectrum disorders. As the Director of the Wolfram Syndrome International Registry and Clinical Study and WFS1 Clinic at Washington University Medical Center (Wolfram Syndrome International Registry & Clinical Study), Dr. Urano has been leading the clinical, translational, and interventional studies of Wolfram syndrome and Wolfram-spectrum disorder. Dr. Urano’s collaboration with colleagues at the medical center and around the world has allowed him to develop cutting-edge treatments for this disease, including gene therapy and regenerative therapy. Dr. Urano is a scientific co-founder and head of the scientific advisory board for Opris Biotechnologies.
Fumihiko “Fumi” Urano, MD, PhD, FACMG, is a Physician and Medical Researcher specializing in Wolfram syndrome, characterized by juvenile-onset diabetes, vision loss, and brain system disruption. Dr. Urano is a Professor of Medicine and Pathology & Immunology, an attending physician, and currently holds Samuel E. Schechter Endowed Professorship in Medicine at Washington University School of Medicine. Dr. Urano is a driving force in the study of Wolfram syndrome and Wolfram-spectrum disorders. As the Director of the Wolfram Syndrome International Registry and Clinical Study and WFS1 Clinic at Washington University Medical Center (Wolfram Syndrome International Registry & Clinical Study), Dr. Urano has been leading the clinical, translational, and interventional studies of Wolfram syndrome and Wolfram-spectrum disorder. Dr. Urano’s collaboration with colleagues at the medical center and around the world has allowed him to develop cutting-edge treatments for this disease, including gene therapy and regenerative therapy. Dr. Urano is a scientific co-founder and head of the scientific advisory board for Opris Biotechnologies.